Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224815 · ClinicalTrials.gov registry record
cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
A clinical trial of CRC, Colorectal Cancer, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT07224815 is a study of CRC, Colorectal Cancer that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 600 participants, above the 261-participant average among 10 other CRC, Colorectal Cancer trials with a reported enrollment target (130% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07224815, a study of CRC, Colorectal Cancer, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The EpiCORE study aims to identify cfDNA-based epigenetic markers predictive of response to first-line chemotherapy (FOLFOX or FOLFIRI) in metastatic colorectal cancer (mCRC). By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to establish a non-invasive biomarker panel capable of distinguishing responders from non-responders.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST cfDNA 5mC/5hmC Sequencing (EpiCORE Discovery Phase)
- DIAGNOSTIC_TEST EpiCORE Assay (Targeted Sequencing / qPCR Validation)
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2026-06-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07224815
The ClinicalTrials.gov registry entry for NCT07224815 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 261-participant average among 10 other CRC, Colorectal Cancer trials with a reported enrollment target (130% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CRC, Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which cfDNA 5mC/5hmC Sequencing (EpiCORE Discovery Phase) is the first listed.
NCT07224815 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07224815 about?
NCT07224815 is a clinical study titled "cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer". The EpiCORE study aims to identify cfDNA-based epigenetic markers predictive of response to first-line chemotherapy (FOLFOX or FOLFIRI) in metastatic colorectal cancer (mCRC). By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to establish a non-inv...
What is the current status of trial NCT07224815?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2024-06-21. Estimated completion is 2026-06-18.
What conditions does trial NCT07224815 study?
This clinical trial studies the following conditions: CRC, Colorectal Cancer.
What interventions are being tested in trial NCT07224815?
The interventions under investigation include: cfDNA 5mC/5hmC Sequencing (EpiCORE Discovery Phase) (DIAGNOSTIC_TEST), EpiCORE Assay (Targeted Sequencing / qPCR Validation) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07224815?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224815 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CRC, Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma
RECRUITING · NA
-
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RECRUITING · Phase 1
-
Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
RECRUITING · Phase 3
-
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.